1 week Ago By ABMN Staff
Shares of Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS – Get Free Report ) have received a consensus rating of “Hold” from the seven research firms that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company.
The average twelve-month price objective among analysts that have covered the stock in the last year is $12.75. Several brokerages recently issued reports on MRNS.
StockNews.com cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th.
Truist Financial reiterated a “buy” rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.
00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Get Our Latest Stock Report on Marinus Pharmaceuticals Institutional Investors Weigh In On Marinus Pharmaceuticals Marinus Pharmaceuticals Stock Performance NASDAQ:MRNS opened at $1.40 on Thursday.
The firm’s fifty day simple moving average is $1.33 and its 200-day simple moving average is $3.40.
The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.
68. The stock has a market cap of $76.91 million, a PE ratio of -0.
53 and a beta of 1.13. Marinus Pharmaceuticals has a fifty-two week low of $1.
05 and a fifty-two week high of $11.26. Marinus Pharmaceuticals ( NASDAQ:MRNS – Get Free Report ) last issued its earnings results on Tuesday, August 13th.
The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.
01). The company had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.
05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.
35%. During the same period last year, the business posted ($0.61) earnings per share.
Analysts expect that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year. About Marinus Pharmaceuticals ( Get Free Report Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.
It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. Featured Articles Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
